Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Stargardt disease Stories

2013-10-22 12:28:28

MaRS client's device unique among low vision aids TORONTO, Oct. 22, 2013 /PRNewswire/ - MaRS client and Investment Accelerator Fund portfolio company eSight Corporation is pleased to announce the launch of eSight eyewear, the first intelligent eyewear that enables people with legal blindness or low vision to see. "eSight has enabled my daughter, Emma Rose, to actually see, something we never thought would be possible," said Jennifer-Anne Gibson. "Emma Rose has been legally...

2012-08-07 22:21:13

OXFORD, England, August 8, 2012 /PRNewswire/ -- -- Treatment of final RetinoStat(R)patient cohort underway -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, and its partner Sanofi (EURONEXT: SAN and NYSE: SNY) today announce a positive interim review of the RetinoStat(R) Phase I study in neovascular "wet" age-related macular degeneration (AMD) and the StarGen(TM) Phase I/IIa study in Stargardt...

2012-07-25 23:00:03

Dr.Burton Feinerman of StemCell RegenMed announces the recruitment of patients diagnosed with Retinitis Pigmentosa, Age related Macular Degeneration and Stargardt Macular Degeneration. Patients with these diseases face the development of blindness at varying age levels. Aventura (N. Miami), Florida (PRWEB) July 25, 2012 Dr.Burton Feinerman of StemCell RegenMed announces the recruitment of patients diagnosed with Retinitis Pigmentosa, Age related Macular Degeneration and Stargardt Macular...

Promising Results In First-ever Trial Of Stem Cell Therapy For The Blind
2012-01-24 06:03:42

Scientists have improved the eyesight of two people who were nearly blind by injecting their eyes with stem cells from human embryos. One patient, a 51-year-old graphic artist, had suffered from Stargardt's disease, the most common form of macular degeneration in young patients, since she was a teenager.  Her condition had progressively worsened to the point she was unable to read a single letter on a standard eye chart and was legally blind. A second patient, aged 78, suffered...

First European Embryonic Stem Cell Trial Approved
2011-09-23 06:30:06

  The first ever European trials of human embryonic stem cell therapy will take place before the end of the year, various media outlets reported on Thursday. According to Guardian Science Correspondent Ian Sample, the trial will take place at Moorfields Eye Hospital in London, and will involve treatment of a form of juvenile blindness known as Stargardt's macular dystrophy. "Massachusetts-based ACT will start the trial of its treatment, which uses retinal pigment epithelium...

2011-07-14 07:30:00

MARLBOROUGH, Mass., July 14, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced the dosing of the first patients in each of its two Phase 1/2 clinical trials for Stargardt's macular dystrophy and dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patients were treated Tuesday (July 12) by Steven Schwartz, M.D.,...

2011-06-27 07:30:00

MARLBOROUGH, Mass., June 27, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has officially granted ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells designation as an orphan medicinal product for the treatment of Stargardt's Macular Dystrophy (SMD). This follows on the U.S....

2011-06-22 01:00:00

OXFORD, England, June 22, 2011 /PRNewswire/ -- - RetinoStat(R) Progress in Phase I Study in Wet Age-Related Macular Degeneration Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that the first dose level of RetinoStat(R) is safe and well-tolerated at one month following treatment. RetinoStat(R) is a novel gene-based treatment for neovascular "wet" age-related macular degeneration (AMD), designed and...

216f1e2c8e43683d7c2bda043fb9a614
2011-06-17 12:40:00

The first two patients with common but incurable diseases of the eye that can lead to blindness have been enrolled early in a two phase groundbreaking clinical trial of therapy that researchers are hoping will heal the damage caused by the conditions. Advanced Cell Technology Inc. (ACT) announced Thursday the enrollment of the patients in the trials for Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD). The patients were enrolled at the Jules Stein Eye...

2011-06-16 07:59:00

MARLBOROUGH, Mass., June 16, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the enrollment of the first patients in its two Phase 1/2 clinical trials for Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patients were enrolled at the Jules Stein Eye Institute at the...